Last updated: 2026-09-06 10:29:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BioCryst Pharmaceuticals Inc. (BCRX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $9.96, with a market capitalization of $2.55B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.00 to $11.22. This page covers its latest market performance, valuation, price trends and company information.
$2.55B | |
$10.00 | |
$23.00 | |
$0.85 | |
$10.09 | |
1.13M | |
4.25M | |
-- | |
$11.22 | |
$6.00 | |
-- | |
-- |
BioCryst Pharmaceuticals Inc. (BCRX) last closed at $10.09 as of 2026-09-04 23:58:00, unchanged from the previous close of $10.09.
During the latest regular trading session, BCRX traded between $0.85 and $23.00, with a volume of 1.13M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, BioCryst Pharmaceuticals Inc. (BCRX) moved from $9.87 to $9.96, representing a gain of 0.86% ($0.09).
The stock traded between $9.46 and $10.23 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 2.56 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 75.8%
BCRX is currently trading at $9.96, placing it 75.8% of the way from its 52-week low of $6.00 to its 52-week high of $11.22. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 435 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioCryst Pharmaceuticals Inc. (BCRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.